Pediatric Psychopharmacotherapy: A Review of Recent Research

Journal of Child Psychology and Psychiatry

Volumn 33, Issue 1, 1992, Pages 153-195

  Gadow, Kenneth D ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

attention deficit hyperactivity disorder; mental retardation; Pharmacotherapy drug therapy; toxicity

Indexed keywords

ALIMEMAZINE; ALPRAZOLAM; AMFEBUTAMONE; BENZATROPINE; BENZODIAZEPINE; BUSPIRONE; CARBAMAZEPINE; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DESMOPRESSIN; DEXAMPHETAMINE; DIPHENHYDRAMINE; FENFLURAMINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; METHYLPHENIDATE; MIDAZOLAM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PEMOLINE; PIMOZIDE; PIRACETAM; PROPRANOLOL; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGGRESSION; ANXIETY NEUROSIS; AUTISM; BEHAVIOR DISORDER; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOTOXICITY; CHILD PSYCHIATRY; COGNITION; COST; DEPRESSION; DRUG ADMINISTRATION; DRUG DOSE; DRUG EFFICACY; ENURESIS; FATIGUE; FEEDING DISORDER; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERACTIVITY; MANIA; MENTAL DEFICIENCY; MOTOR DYSFUNCTION; OBSESSION; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEIZURE; SLEEP DISORDER; VERTIGO; XEROSTOMIA;

EID: 0026541567     PISSN: 00219630     EISSN: 14697610     Source Type: Journal    
DOI: 10.1111/j.1469-7610.1992.tb00861.x     Document Type: Article

References (304)

1. Cognitive training in academically deficient ADDH boys receiving stimulant medication
2. The normalizing effects of methylphenidate on the classroom behavior of ADDH children
3. Hyperactive children treated with stimulants: is cognitive training a useful adjunct?
4. Review of fenfluramine in the treatment of the developmental disabilities
5. Clinical effects of methylphenidate and thioridazine in intellectually subaverage children
6. Methylphenidate and thioridazine in the treatment of intellectually subaverage children. Effects on cognitive‐motor performance
7. Pharmacological intervention
8. Haloperidol treatment with chronically medicated residents: dose effects of clinical behavior and reinforcement contingencies
9. Methylphenidate and diazepam in severe reading retardation
10. Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents
11. Preliminary study of imipramine in profoundly retarded residents
12. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children
13. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms
14. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers
15. Hyperactive girls and boys: stimulant drug effects on mother‐child interactions
16. The effects of methylphenidate on the mother‐child interactions of hyperactive children
17. Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate
18. Development of a multimethod clinical protocol for assessing stimulant drug response in children with attention deficit disorder
19. Developmental changes in the mother‐child interactions of hyperactive boys: effects of two dose levels of Ritalin
20. The response of aggressive and nonaggressive ADHD children of two doses of methylphenidate
21. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systematic, placebo‐controlled evaluation
22. Effects of naloxone and naltrexone on self‐injury: a double‐blind, placebo‐controlled analysis
23. Treatment of self‐injury and disruptive behavior with carbamazepine (Tegretol) and behavior therapy?
24. Pediatric cardiovascular effects of imipramine and desipramine
25. Urinary dopamine metabolites as indicators of the responsiveness to fenfluramine treatment in children with autistic disorder
26. School phobia: a therapeutic trial with clomipramine and short‐term outcome
27. Comparative studies of pharmacotherapy for school refusal
28. Effects of narcotic antagonists on self‐injurious behavior: a single case study
29. Sudden death in children treated with a tricyclic antidepressant
30. A double‐blind placebo controlled study of desipramine in the treatment of ADD, I. Efficacy
31. A double‐blind placebo controlled study of desipramine in the treatment of ADD. II. Serum drug levels and cardiovascular findings
32. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety and other disorders
33. Methylphenidate treatment of hyperactive autistic children
34. The psychopharmacology of nocturnal enuresis
35. Midazolam for aggressivity and violence in three mentally retarded patients
36. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability
37. The behavior of children receiving Benzedrine
38. Benzedrine and Dexedrine in the treatment of children's behaviour disorders
39. School performance of children receiving amphetamine (Benzedrine) sulfate
40. Transdermal scopolamine in drooling
41. Depression following pemoline withdrawal in a hyperactive child
42. Methylphenidate and cognitive therapy with ADD children: a methodological consideration
43. A controlled trial of methylphenidate in Black adolescents: attentional, behavioral, and physiological effects
44. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder
45. Clinical behavioural pharmacology: methods for evaluating medications and contingency management
46. Fenfluramine treatment of autism
47. Tardive dyskinesia and withdrawal dyskinesia in autistic children: a prospective study
48. A comparison of haloperidol and behavior therapy and their interaction in autistic children
49. Naltrexone in autistic children: a double‐blind and placebo‐controlled study
50. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children
51. Naltrexone in autistic children: an acute open dose range tolerance trial
52. Long‐term therapeutic efficacy and drug‐related abnormal movements: a prospective study of haloperidol in autistic children
53. Behavioural efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder
54. Efficacy of benztropine therapy for drooling
55. Classification issues of bipolar disorder in childhood
56. The neuroleptic malignant syndrome
57. Clonidine in Tourette's syndrome
58. Behavioural effects of haloperidol in young autistic children: an objective analysis using a within subjects reversal design
59. Tourette's syndrome and attention deficit disorder with hyperactivity: are they genetically related?
60. Psychological effects of stimulant drugs in children with minimal brain dysfunction
61. Classification and treatment of childhood depression and depressive equivalents
62. Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder. II. Information processing
63. The use of methylphenidate in children with seizures and attention deficit disorder
64. A developmental dose‐response analysis of the effects of methylphenidate on the peer interactions of attention deficit disordered boys
65. A dose‐response analysis of the effects of methylphenidate on the peer interactions and simulated classroom performance of ADD children with and without conduct problems
66. The effect of milenperone on the aggressive behavior of oligophrenic patients
67. Long‐term experience with lithium treatment in childhood: correlation with clinical diagnosis
68. A case of neuroleptic malignant syndrome in a mentally retarded adolescent
69. The effects of piracetam in children with dyslexia
70. Fenfluramine and dextroamphetamine treatment of childhood hyperactivity
71. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response
72. Dosage effects and individual responsivity to methylphenidate in attention deficit disorder
73. Short term effects of methylphenidate on the cognitive, learning and academic performance of children with attention deficit disorder in the laboratory and the classroom
74. Fenfluramine treatment of twenty children with autism
75. Gilles de la Tourette's syndrome: effects of stimulant drugs
76. Carbamazepine in pediatric psychiatry
77. The failure of antimotion sickness medication to improve reading in developmental dyslexia: results of a randomized trial
78. Propranolol treatments for childhood post traumatic stress disorder, acute type
79. Psychopharmacology of self‐injurious behaviour in the mentally retarded
80. A single‐subject study of imipramine in a mentally retarded woman with depressive symptoms
81. Active drug placebo trial of methylphenidate; a clinical service for children with attention deficit disorder
82. A treatable language disorder: pharmacological treatment of pervasive developmental disorder
83. Clomipramine treatment of childhood obsessive‐compulsive disorders
84. Relative efficacy of pharmacological, behavioral, and combination treatments for enhancing academic performance
85. Prevalence and efficacy of stimulant drug use with mentally retarded children and youth
86. Pharmacotherapy
87. A school‐based medication evaluation program
88. Prevalence and pattern of drug treatment for behaviour and seizure disorders in TMR students
89. A procedure for assessing the effects of methylphenidate on hyperactive school children in public school settings
90. Methylphenidate in aggressive‐hyperactive boys, I. Effects on peer aggression in public school settings
91. A controlled case study of methylphenidate and fenfluramine in a young mentally retarded, hyperactive child
92. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk
93. Neuroendocrine and cognitive responses to amphetamine in adolescents with a history of attention deficit disorder
94. Haloperidol in the treatment of stuttering
95. Prospective study of scheduled withdrawal from nortriptyline in children and adolescents
96. Double‐blind placebo‐controlled study of nortriptyline in depressed adolescents using a “fixed plasma level” design
97. Double‐blind placebo‐controlled study of nortiptyline in depressed children using a “fixed plasma level” design
98. Haloperidol‐induced comatose state with hyperthermia and rigidity in adolescence: two case studies with a literature review
99. Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity
100. Children with reading disorders–II. Effects of methylphenidate in combination with reading remediation
101. Pharmacotherapy of childhood anxiety disorders
102. Controlled imipramine treatment of school phobia
103. Are behavioral and psychometric changes related in methylphenidate‐treated, hyperactive children?
104. Methylphenidate effects in learning disabilities
105. Rapid cycling affective disorders in the mentally retarded
106. Clonidine and Gilles de la Tourette's syndrome: double‐blind study using objective rating methods
107. Anorexia nervosa and bulimia nervosa
108. Systematic dyskinesia examination of profoundly mentally retarded persons: co‐operation and assessment
109. Molindone hydrochloride treatment of hospitalized children with conduct disorder
110. Suspected adverse methylphenidate‐imipramine interactions in children
111. Motor performance in hyperactive children treated with stimulants
112. Tardive dyskinesia in young mentally retarded individuals
113. Tardive dyskinesia litigation and the dilemmas of neuroleptic treatment
114. Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder
115. Adverse side effect of methylphenidate among mentally retarded children with ADHD
116. Imipramine dosage in children: a comment on “Imipramine and electrocardiographic abnormalities in hyperactive children”
117. Stimulant drug treatment of four multihandicapped children using a randomized single‐case design
118. Anger control in response to verbal provocation: effects of stimulant medication for boys with ADHD
119. Aggressive, prosocial, and nonsocial behaviour in hyperactive boys: dose effects of methylphenidate in naturalistic settings
120. Additive effects of psychostimulants, parent training, and self‐control therapy with ADHD children
121. The effect of concomitant disorders in childhood depression on predicting treatment response
122. Stimulant effects on cooperation and social interaction between hyperactive children and their mothers
123. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double‐blind placebo‐crossover therapeutic trial
124. Pemoline and liver function
125. Neuroleptic malignant syndome in pregnancy
126. Therapeutic use of propranolol for intermittent explosive disorder
127. Expressions of the hyperventilation syndrome in childhood
128. Low‐dose neuroleptic therapy for childhood‐onset pervasive developmental disorder
129. Effects of psychotropic drugs on cognition and memory in normal humans and animals
130. Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction and nonneuroleptic history groups: preliminary results
131. Tardive dyskinesia: update for the mental health administrator
132. Training clinical personnel to assess for tardive dyskinesia
133. Amitriptyline in children with major depressive disorder: a double‐blind crossover pilot study
134. Valproic acid for the treatment of children with mental retardation and mood symptomatology
135. Lithium carbonate in juveiine manic‐depressive illness
136. Emergence of self‐destructive phenomena in children and adolescents during fluoxetine treatment
137. Clinical efficacy and safety of desmopressin in the treatment of noctural enuresis
138. Methylphenidate and growth in hyperactive children: a controlled withdrawal study
139. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height
140. Clinical effects of a controlled trial of methylphenidate on adolescents with attention deficit disorder
141. Effects of methylphenidate on attention‐deficit hyperactivity disorder with and without aggressive/noncompliant
142. Effects of methylphenidate on adolescents with a childhood history of attention deficit disorder
143. Double‐blind, placebo‐controlled stimulant trial in children with Tourette's syndrome and attention‐deficit hyperactivity disorder
144. Characteristics of narcolepsy in preteenaged children
145. Clinical effects of amitriptyline in adolescent depression: a pilot study
146. Use of propranolol to decrease aggressive outbursts in younger patients
147. Clonazepam treatment of adolescents with neuroleptic‐induced akathisia
148. Antistuttering medication?
149. A retrospective study of mentally retarded patients with behavior disorders
150. Clonidine treatment of Gilles de la Tourette's syndrome
151. Rebound phenomena in Tourette's syndrome after abrupt withdrawal of clonidine
152. Treatment of obsessive‐compulsive disorder with clomipramine and desipramine in children and adolescents
153. Thioridazine metabolism and effects on stereotyped behavior in mentally retarded patients
154. Tourette syndrome, pimozide and school phobia: the neuroleptic separation anxiety syndrome
155. Carbamazepine (Tegretol) in epilepsy: nine year follow‐up study with special emphasis on untoward reactions
156. Stimulant medications precipitate Tourette's syndrome
157. Pipothiazine palmitate in the management of aggressive mentally handicapped patients
158. An individual double‐blind crossover trial for assessing methylphenidate response in children with attention deficit disorder
159. Methylphenidate in therapeutic doses does not lower seizure threshold
160. Bipolar disorder in mentally retarded adolescents
161. Neuroleptic malignant syndrome in a man with mental retardation
162. Differentiation of stereotypes for neuroleptic‐related dyskinesis in autistic
163. Diagnosis and pharmacotherapy of schizophrenia in the retarded
164. The neuroleptic malignant syndrome in an adolescent
165. Low‐dose haloperidol for sterotypic self‐injurious behavior in the mentally retarded
166. School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder
167. Noctural enuresis: experience with long‐term use of intranasally administered desmopressin
168. Clopenthixol decanoate in the management of aggressive mentally handicapped patients
169. Effect of benzedrine sulfate on children taking New Stanford Achievement Test
170. Evaluating drug effectiveness in an office setting for children with attention deficit disorders
171. The hyperkinetic syndrome in epileptic children
172. Tardive dyskinesia as a possible sequel of long‐term therapy with the phenothiazines
173. Treatment of ADDH in mentally retarded children: a preliminary study
174. Methylphenidate and children with attention deficit disorder: dose effects on classroom academic and social behaviour
175. Relative efficacy of long‐acting stimulants on children with attention deficit‐hyperactivity disorder: a comparison of standard methylphenidate, sustained‐release methylphenidate, sustained‐release dextroamphetamine, and pemoline
176. Behavioral assessment of psychostimulant effects on ADD children in a summer day treatment program
177. Methylphenidate and baseball playing in ADHD children: who's on first?
178. Effects of continuous and partial reinforcement and methylphenidate on learning in children with attention deficit disorder
179. Attention deficit and conduct disorders
180. The combination of behavior therapy and methylphenidate in the treatment of attention deficit disorder: a therapy outcome study
181. The effects of sustained release 20 and 10 mg Ritalin b.i.d. on cognitive and social behaviour in children with attention deficit disorder
182. Comparative effects of methylphenidate on ADD girls and ADD boys
183. Effects of methylphenidate on normal children's mood, event‐related potentials, and performance in memory scanning and vigilance
184. The genetics of dyslexia
185. Long‐term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration
186. Imipramine treatment of depressed children: a double‐blind pilot study
187. Alprazolam in the treatment of anticipatory and acute situational anxiety in children with cancer
188. Mania and neuropsychiatric excitation following carbamazepine
189. Tricyclic antidepressants in the treatment of children with attention deficit disorder
190. Effect of anxiety on cognition, behavior, and stimulant response in ADHD
191. The treatment of impulsive and aggressive behaviour with nadolol
192. A controlled evaluation of loxitane in seventy‐five adolescent schizophrenic patients
193. Gilles de la Tourette's syndrome: tics and central nervous system stimulants in twins and nontwins
194. The use of Benzedrine for the treatment of narcolepsy
195. Imipramine in prepubertal major depressive disorders
196. Tardive dyskinesia in neuroleptic medicated mentally‐handicapped subjects
197. Psychopharmacology of childhood depression
198. Controlled studies of the effects of psychostimulants on children's classroom behavior and academic functioning
199. Comparing classroom and clinical measures of attention deficit disorder: differential, idiosyncratic and dose‐response effects of methylphenidate
200. Attention deficit disorder and methylphenidate: group and single‐subject analyses of dose effects on attention in clinic and classroom samples
201. Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance
202. Attention deficit disorder and methylphenidate: multilevel analysis of dose‐response effects on children's impulsivity across settings
203. b‐Blockers in the severely and profoundly mentally retarded
204. Autism: the treatment of aggressive behaviours
205. Buspirone therapy for malActaptive behaviour and anxiety in developmentally disabled persons
206. Clinical effect of busipirone in autistic children
207. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents
208. Evaluation of flurozepam and placebo on sleep disorders in childhood
209. What is the role of academic intervention in the treatment of hyperactive children with reading disorders?
210. Effects of methylphenidate dosage in hyperactive reading‐disabled children. II. Reading achievement
211. The prevalence of tardive dyskinesia in a mentally retarded population
212. A double‐blind drug trial of treatment in young children with waking problems
213. Desipramine treatment of boys with attention‐deficit hyperactivity disorder and tics: preliminary clinical experience
214. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience
215. Sudden death in children receiving Norpramin: a review of three reported cases and commentary
216. The effects of stimulant medication on the growth of hyperkinetic children
217. Beta adrenergic blocking agents for aggressive or self‐injurious mentally retarded persons
218. The effectiveness of diphenhydramine HC1 in pediatric sleep disorders
219. Lithium antidepressant augmentation of TC A‐refractory depression in adolescents
220. Imipramine in adolescent major depression: plasma level and clinical response
221. Relative safety of single versus divided dose imipramine in adolescent major depression
222. MAOIs in adolescent major depression unresponsive to tricyclic antidepressants
223. A survey of medication treatment for hyperactive/inattentive students
224. Pemoline‐induced abnornal involuntary
225. An orally administered opiate blocker, nahrexonc. attenuates self‐injurious behavior
226. Imipramine side effects in children
227. Therapeutic interventions to prevent delinquency in hyperactive boys
228. The concurrent assessment of behavioral and psychostimulant interventions: a controlled case study
229. Behavioral interactions induced by chronic neuroleptic therapy in persons with mental retardation
230. Cardiovascular effects of desipramine in children
231. Fenfluramine in Prader‐Willi syndrome: a double blind, placebo controlled trial
232. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome
233. The effects of fenfluramine (hydrochloride) on the behaviours of fifteen autistic children
234. Results of treatment with clozapine in schizophrenic adolescents
235. Propranotol for aggression: literature review and clinical guidelines
236. Alprazolam effects in children with anxiety disorders
237. Treatment of adolescent obsessive‐compulsive disorder with a clomipramine‐fluoxetine combination
238. Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment
239. Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome
240. Attention deficit disorder with hyperactivity and the dopamine hypothesis: case presentations with theoretical background
241. The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders
242. Do the mentally retarded suffer from affective illness?
243. Effects of dextroamphetamine and contingency management on a preschooler with ADHD and oppositional defiant disorder
244. Psychometic properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS)
245. Toward a movement control perspective of tardive dyskinesia
246. Effects of psychopharmacologic agents on learning disorders
247. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behaviour
248. Methodology of psychopharmacological studies with the retarded
249. Lithium responsive manic‐like symptoms in two individuals with autism and mental retardation
250. A controlled crossover trial of fenfluramine in autism
251. Lifetime antipsychotic‐drug exposure, dyskinesia and related movement disorders in the developmentally disabled
252. Prevalence of dyskinesia and related movement disorders in a developmentally disabled population
253. Randomized trial of methylphenidate for an autistic child
254. The pharmacotherapy of depressive illness in adolescence. I. An open label trial on imipramine
255. Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: a naturalistic study
256. Methylphenidate treatment of attention‐deficit hyperactivity disorder in boys with Tourette syndrome
257. Obsessive‐compulsive disorder in children and adolescents
258. Haldol in the treatment of children with tics and stutterers‐an incidental finding
259. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour
260. Neuroleptic drugs: indications and guidelines for their rational use in children and adolescents
261. The neuroleptic malignant syndrome: occurrence in a 15–year‐old boy and recovery with bromocriptine therapy
262. Temporary changes in affect and attitude following ingestion of various amounts of Benzedrine sulfate (amphetamine sulfate)
263. Factors associated with a good response in aggressive mentally handicapped subjects
264. Responders, nonresponders, and placebo responders among children with attention deficit disorder
265. Lithium treatment of manic episodes with psychotic features in prepubertal children
266. A two‐year follow‐up of autistic children treated with fenfluramine
267. Dyslexia
268. Therapeutic experience with lithium in childhood aggressivity
269. Effects of methylphenidate on early adolescent growth
270. Stimulant medication in certain childhood disorders
271. The effects of methylphenidare on learning in children with ADHD: the stimulus equivalence paradigm
272. The nature of phonological processing and its causal role in the acquisition of reading skills
273. Effects of methylphenidate hydrochloride on the subjective reporting of mood in children with attention deficit disorder
274. Classroom social interactions of attention deficit disorder with hyperactivity children as a function of stimulant medication
275. A case report of nahrexone treatment of self‐injury and social withdrawal in autism
276. Neuroleptic malignant syndrom with hypomania and mental retardation
277. Lithium dosage guide for prepubertal children: a preliminary report
278. Controlled trial of the treatment of 36 stutterers
279. Drugs, learning and cognitive function in children: an update
280. Does stimulant medication improve the peer status of hyperactive children
281. Methylphenidate and hyperactivity: effects on teacher behaviors
282. Natural social behaviors in hyperactive children: dose effects of methylphenidate
283. Pimozide treatment in disruptive severely retarded patients
284. Comparison of sustained release and standard methylphenidate in the treatment of minimal brain dysfunction
285. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction
286. Imipramine and electrocardiographic abnormalities in hyperactive children